Institution · Teva Pharmaceuticals (Israel)

Most cited papers from Teva Pharmaceuticals (Israel)

Teva Pharmaceuticals (Israel)

What are the most cited papers from Teva Pharmaceuticals (Israel)?

The most cited paper from Teva Pharmaceuticals (Israel) is "Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies" (Doron Lipson et al., 2012), with 873 citations. Next come "Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial" (445) and "Drug repurposing from the perspective of pharmaceutical companies" (440).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 85 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Doron Lipson et al. · Nature Medicine Open access	12 Feb 2012	873
2	Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning et al. · The Lancet	16 Aug 2019	445
3	Drug repurposing from the perspective of pharmaceutical companies Yoonjeong Cha, T. Erez, Ian J. Reynolds et al. · British Journal of Pharmacology Open access	29 Mar 2017	440
4	Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial Jerry S. Wolinsky, Ponnada A. Narayana, Paul W O'Connor et al. · Annals of Neurology Open access	2007	432
5	Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels Leif Bjermer, Catherine Lemière, Jorge Fernando Maspero et al. · CHEST Journal Open access	4 Apr 2016	431
6	Choosing an animal model for the study of Huntington's disease Mahmoud A. Pouladi, A. Jennifer Morton, Michael R. Hayden · Nature reviews. Neuroscience Review	20 Sep 2013	372
7	Markers Distinguishing Mesenchymal Stem Cells from Fibroblasts Are Downregulated with Passaging Svetlana Halfon, Natalie Abramov, Borislava Grinblat et al. · Stem Cells and Development	7 Jun 2010	328
8	Guidelines for preclinical animal research in ALS/MND: A consensus meeting Albert Christian Ludolph, Caterina Bendotti, Eran Blaugrund et al. · Amyotrophic Lateral Sclerosis Open access	2010	318
9	A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye Smadar Cohen, Esther Löbel, Amira Trevgoda et al. · Journal of Controlled Release	17 Feb 1997	298
10	Discovery of Metabolomics Biomarkers for Early Detection of Nephrotoxicity Kurt J. Boudonck, Matthew W. Mitchell, László Német et al. · Toxicologic Pathology	Apr 2009	252
11	Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease JEFFREY J. STERLING et al. · Journal of Medicinal Chemistry Open access	23 Oct 2002	252
12	Rhodobacteraceaeare the key members of the microbial community of the initial biofilm formed in Eastern Mediterranean coastal seawater Hila Elifantz, Gilad Horn, Meir Ayon et al. · FEMS Microbiology Ecology Open access	29 Mar 2013	243
13	The management of cancer pain Nathan I. Cherny · CA A Cancer Journal for Clinicians Open access	Mar 2000	216
14	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes Olivier Rascol, Cheryl J. Fitzer‐Attas, Robert A. Hauser et al. · The Lancet Neurology	9 Apr 2011	213
15	Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis Marcia L. Moss, Liora Sklair‐Tavron, Raphael Nudelman · Nature Clinical Practice Rheumatology	15 Apr 2008	200
16	A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis On behalf of the BRAVO Study Group, Timothy R. Vollmer, Per Soelberg Sørensen et al. · Journal of Neurology	17 Feb 2014	197
17	Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination Wolfgang Brück, Ramona Pförtner, Trinh Pham et al. · Acta Neuropathologica Open access	5 Jul 2012	176
18	A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics C. Warren Olanow, Robert A. Hauser, Joseph J. Jankovic et al. · Movement Disorders	19 Oct 2008	167
19	Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery Aaron J. Courtenay, Emma McAlister, Maelíosa McCrudden et al. · Journal of Controlled Release Open access	19 Mar 2020	160
20	Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Socrates E. Papapoulos, Sara A. Quandt, Uri A. Liberman et al. · Osteoporosis International Review	20 Sep 2004	154
21	Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer Marina Pekar‐Zlotin, Fred R. Hirsch, Lior Soussan‐Gutman et al. · The Oncologist Open access	26 Feb 2015	148
22	Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma Kevin R. Murphy, Joshua Jacobs, Leif Bjermer et al. · The Journal of Allergy and Clinical Immunology In Practice Open access	Nov 2017	147
23	Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor Joel Kaye, Victor Piryatinsky, Tal Birnberg et al. · Proceedings of the National Academy of Sciences Open access	26 Sep 2016	143
24	A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients Corey C. Ford, K. P. Johnson, Robert P. Lisak et al. · Multiple Sclerosis Journal	23 Apr 2006	139
25	Predicting Phenotype from Genotype: Normal Pigmentation* Robert K. Valenzuela, M. Henderson, Monica H. Walsh et al. · Journal of Forensic Sciences Open access	11 Feb 2010	137
26	Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor Jan Thöne, Gisa Ellrichmann, Silvia Seubert et al. · American Journal Of Pathology Open access	9 Dec 2011	133
27	The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease Daniel A. Ryskamp, Jun Wu, Michal Geva et al. · Neurobiology of Disease Open access	3 Nov 2016	132
28	Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer Nir Peled, Gary A. Palmer, Fred R. Hirsch et al. · Journal of Thoracic Oncology Open access	15 Aug 2012	132
29	Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone® Talma Brenner, Ruth Arnon, Michael Sela et al. · Journal of Neuroimmunology	Apr 2001	130
30	Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model Stefan Waibel, Alexander Reuter, Susanne Malessa et al. · Journal of Neurology	Sep 2004	127
31	Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils Guy Brusselle, Matthew Germinaro, Sivan Weiss et al. · Pulmonary Pharmacology & Therapeutics Open access	31 Jan 2017	126
32	Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease Robert A. Hauser, Mark Lew, Howard I. Hurtig et al. · Movement Disorders	11 Dec 2008	126
33	Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy Huda Mussaffi, Joseph Rivlin, Itamar Shalit et al. · European Respiratory Journal Open access	31 Jan 2005	123
34	Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models Sònia Marco, Albert Giralt, Milos M. Petrovic et al. · Nature Medicine Open access	14 Jul 2013	122
35	Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis Christiane Wegner, Christine Stadelmann, Ramona Pförtner et al. · Journal of Neuroimmunology Open access	4 Aug 2010	121
36	How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider Huub Schellekens, Sven Stegemann, Vera Weinstein et al. · The AAPS Journal Open access	25 Sep 2013	121
37	Topical Treatment of Cutaneous Leishmaniasis Joseph El-On, Rita Livshin, Z. Even‐Paz et al. · Journal of Investigative Dermatology Open access	Aug 1986	119
38	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses Gavin Giovannoni, Gary Cutter, Maria Pia Sormani et al. · Multiple Sclerosis and Related Disorders Open access	17 Jan 2017	117
39	Evaluation of Bone Marrow-Derived Mesenchymal Stem Cells After Cryopreservation and Hypothermic Storage in Clinically Safe Medium Irene Ginis, Borislava Grinblat, Mitchell Shirvan · Tissue Engineering Part C Methods	26 Dec 2011	115
40	Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop Albert Christian Ludolph, Caterina Bendotti, Eran Blaugrund et al. · Amyotrophic Lateral Sclerosis	2007	113
41	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study Ralf Reilmann et al. · The Lancet Neurology 120 authors	15 Dec 2018	112
42	The therapeutic equivalence of complex drugs Huub Schellekens, Ety Klinger, Stefan Mühlebach et al. · Regulatory Toxicology and Pharmacology	15 Oct 2010	111
43	Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study Kara M. Smith, Eli Eyal, Daniel A. Weintraub · JAMA Neurology	24 Nov 2014	108
44	Mechanisms compensating for dopamine loss in early Parkinson disease Jonathan M. Brotchie, Cheryl J. Fitzer‐Attas · Neurology	17 Feb 2009	103
45	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial Werner H Poewe, Klaus Seppi, Cheryl J. Fitzer‐Attas et al. · The Lancet Neurology	7 Dec 2014	99
46	Molecular imaging of cell death in vivo by a novel small molecule probe Revital Ben-Aziz Aloya, Anat Shirvan, Hagit Grimberg et al. · APOPTOSIS Open access	17 Oct 2006	99
47	Newcastle disease vaccines Gilad E. Gallili, David Ben‐Nathan · Biotechnology Advances	Mar 1998	98
48	Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor John J. Thébault, Michel Guillaume, Ruth Levy · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	14 Sep 2004	97
49	Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis Timothy R. Vollmer, HILLEL S. PANITCH, Amit Bar‐Or et al. · Multiple Sclerosis Journal	18 Apr 2008	95
50	Laquinimod reduces neuroaxonal injury through inhibiting microglial activation Manoj Kumar Mishra, Janet Wang, Michael B. Keough et al. · Annals of Clinical and Translational Neurology Open access	26 May 2014	95

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.